WuXi AppTec provides a comprehensive portfolio of research, development and manufacturing services to pharmaceutical, biotechnology and medical device companies worldwide. Leveraging integrated platforms that span small-molecule drug discovery, biologics development and cell- and gene-therapy solutions, the company supports clients through every phase of the product life cycle, from candidate identification and preclinical testing to clinical manufacturing and commercial production.
The company’s service offerings include medicinal chemistry, in vitro and in vivo pharmacology, toxicology studies, bioanalytical and molecular testing, as well as process development and GMP manufacturing for both small molecules and biologics. WuXi AppTec also offers specialty services in cell therapy, gene therapy, personalized medicine and advanced therapies, alongside medical device testing and regulatory support to streamline development pathways and accelerate time to market.
Founded in 2000 and headquartered in Shanghai, WuXi AppTec has built a global network of research laboratories, development centers and manufacturing facilities in China, the United States, Europe and Asia-Pacific. This international footprint enables the company to serve more than 3,000 clients, including large pharmaceutical firms, emerging biotech companies and academic institutions, with flexible project engagements and scalable capacity.
Dr. Ge Li, the company’s founder, serves as chairman and chief executive officer, guiding a leadership team of seasoned industry professionals. Under their stewardship, WuXi AppTec has forged strategic alliances and invested in cutting-edge technologies to enhance its end-to-end R&D capabilities and address the evolving needs of the global life-sciences community.
AI Generated. May Contain Errors.
Free WUXIF Stock Alerts